Natera, Inc.

Natera Oncology leads in precision oncology by utilizing advanced cell-free DNA technology to provide personalized, longitudinal molecular insights across the entire cancer care continuum. This personalized genomic data helps clinicians optimize management, monitor disease progression, and detect cancer recurrence earlier than traditional methods. Natera's innovative diagnostic portfolio features Signatera™ for personalized molecular residual disease (MRD) assessment, Latitude™ for tissue-free residual disease testing, Altera™ for comprehensive genomic profiling, and Empower™ for hereditary cancer risk evaluation. Together, these advanced genomic tools enable informed treatment strategies, and ultimately help improve overall long-term clinical outcomes for patients.